Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market : Technology Advancements, Industry Insights, Trends And Forecast 2033

Overview and Scope
Methicillin-resistant Staphylococcus aureus (MRSA) drugs refer to a group of drugs used to treat infections caused by the bacterium Staphylococcus aureus that are resistant to methicillin and other common antibiotics. These drugs are specifically chosen to target and kill MRSA bacteria or inhibit their growth. MRSA is a source of staph infections that is challenging to treat due to antibiotic resistance.

Sizing and Forecast
The methicillin-resistant staphylococcus aureus (mrsa) drugs market size has grown strongly in recent years. It will grow from $2.26 billion in 2023 to $2.38 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to antibiotic resistance concerns, hospital-acquired infections, surgical procedures, global increase in mrsa cases, high mortality rates..

The methicillin-resistant staphylococcus aureus (mrsa) drugs market size is expected to see strong growth in the next few years. It will grow to $2.9 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to continued antibiotic resistance challenges, advancements in mrsa diagnostics, global healthcare-associated infections, preventive measures in surgery, rising community-acquired mrsa cases.. Major trends in the forecast period include exploration of immunomodulators, strategic partnerships for drug development, customized therapies based on strain characteristics, focus on pediatric-specific formulations, global health initiatives to combat antibiotic resistance..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-global-market-report

The methicillin-resistant staphylococcus aureus (mrsa) drugs market covered in this report is segmented –

1) By Drug Class: Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Lipoglycopeptide, Other Drug Classes
2) By Indication: Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections
3) By MRSA Type: Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA)
4) By Route of Administration: Oral Administration, Parenteral Administration
5) By End User: Hospitals and Clinics, Research and Academic Institutes, Other End-Users

North America was the largest region in the global methicillin-resistant staphylococcus aureus drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10859&type=smp

Major Driver Impacting Market Growth
The increase in the prevalence of methicillin-resistant Staphylococcus aureus infections is expected to propel the growth of the methicillin-resistant Staphylococcus aureus drugs market going forward. A methicillin-resistant Staphylococcus aureus (MRSA) infection is caused by Staphylococcus bacteria that is resistant to some antibiotics used for treating ordinary staph infections. MRSA infections must be treated with drugs that destroy and inhibit the growth of MRSA bacteria in humans and animals. For instance, in November 2022, according to the Centers for Disease Control and Prevention, a US-based health agency under the Department of Health and Human Services, hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections increased by 14% from 2020 to 2021. Further, in December 2022, according to a report by Statens Serum Institute, a Denmark-based sector research institute on MRSA – disease prevalence, in 2021, the number of community-acquired infections with recorded contact with a hospital or the nursing sector in the previous six months was 181, up from 159 in 2020. Therefore, the increase in the prevalence of methicillin-resistant Staphylococcus aureus infections is driving the growth of the methicillin-resistant Staphylococcus aureus drug market.

Key Industry Players
Major companies operating in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Basilea Pharmaceutica Ltd., Merck & Co Inc., Pfizer Inc., Theravance Biopharma Inc., Allergan plc, Cumberland Pharmaceuticals Inc., Debiopharm International S.A., The Medicines Company, AbbVie Inc., Innovation Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Absynth Biologics, AmpliPhi Biosciences Corporation, AstraZeneca plc, 3M Co., Meiji Seika Kaisha Ltd., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Novartis, Wockhardt, Sun Pharmaceutical Industries Ltd., Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Astellas Pharma Inc.

The methicillin-resistant staphylococcus aureus (mrsa) drugs market report table of contents includes:

1. Executive Summary

2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Characteristics

3. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Trends And Strategies

4. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market – Macro Economic Scenario

5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Size and Growth
………..

31. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Benchmarking

32. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

34. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Future Outlook and Potential Analysis

35. Appendix

Related Reports:

https://goodprnews.com/glycinates-market-overview/

https://goodprnews.com/heat-shrink-tubing-and-sleeves-market-share/

https://goodprnews.com/high-reliability-semiconductors-market-forecast/

https://goodprnews.com/hypodermic-syringes-and-needles-market-trends/

https://topprnews.com/glycinates-market-segment/

https://topprnews.com/heat-shrink-tubing-and-sleeves-market-drivers/

https://topprnews.com/high-reliability-semiconductors-market-outlook/

https://topprnews.com/hypodermic-syringes-and-needles-market-players/

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model